What is iBio, Inc.'s earnings per share (EPS)?

iBio, Inc. (IBIO) reported diluted earnings per share of -$0.32 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

iBio, Inc. (IBIO) Financials

IBIO

FY2026 annual

Revenue $100K -75.0% YoY

Net Income -$32.8M -78.7% YoY

EPS (Diluted) -$0.32 YoY not available

Free Cash Flow -$23.8M -55.3% YoY

Market Cap $54.0M as of Oct 21, 2026

Price / Sales 540x on $100K revenue, FY2026

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 0.6x on $85.7M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 28, 2026 Currency USD FYE June

Newest figures come from the 10-K for FY2026, filed Aug 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IBIO SEC filings page.

iBio, Inc. (IBIO) reported $100K in revenue for fiscal year 2026, down 75.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IBIO FY2026 2026-10-04

iBio operates as a development-stage business: financing supplies its balance sheet while research spending remains far ahead of revenue.

In FY2026, R&D spending was $19.6M against revenue of $100K, so reported activity remains development-led rather than commercially scaled. Operating cash flow of -$23.2M closely tracked free cash flow of -$24.0M, indicating that the cash need comes primarily from ongoing operations rather than heavy capital spending.

FY2026 financing inflow of $103.0M lifted total assets to $99.1M, so the year's balance-sheet expansion was financing-led rather than generated by operations. A debt-to-equity ratio of 0.2x and current ratio of 7.9x describe low debt and ample reported short-term coverage, but not operating self-funding.

The latest net loss of $32.8M exceeded operating cash outflow of $23.2M, showing that accounting loss and immediate cash use are not interchangeable. The reported liquidity measure was 45.5 months of FY2026 operating outflow, a balance comparison that is materially larger than one year's reported operating cash need, not evidence of break-even.

Financial Health Signals

Financial health score not available

iBio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-2.94

iBio, Inc. scores -2.94, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($54.0M) relative to total liabilities ($13.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

iBio, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

iBio, Inc. reported a net loss of $32.8M while operations used $23.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

iBio, Inc. reported an operating loss of $35.1M against $53K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$0.07

QoQ-16.7%

iBio, Inc. earned -$0.07 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 16.7%.

Revenue

Not reported for Q4 2026.

EBITDA

Not reported for Q4 2026.

Net Income

Not reported for Q4 2026.

Cash & Balance Sheet

Free Cash Flow

-$6.2M

YoY-35.3%

QoQ-2.5%

iBio, Inc. recorded an outflow of $6.2M in free cash flow in Q4 2026, representing a cash shortfall after capex. This represents a decrease of 35.3% from the same quarter a year earlier. Against the prior quarter it is down 2.5%.

Cash & Debt

$56.4M

YoY+557.1%

QoQ+18.4%

5Y CAGR-6.1%

10Y CAGR+13.5%

iBio, Inc. held $56.4M in cash as of Q4 2026; long-term debt is not reported for that period.

Shares Outstanding

64M

QoQ+29.4%

5Y CAGR-21.7%

10Y CAGR-3.2%

iBio, Inc. had 64M shares outstanding in Q4 2026. Against the prior quarter it is up 29.4%.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

None of these metrics is reported for Q4 2026.

Capital Allocation

Capital Expenditures

$19K

YoY+1800.0%

QoQ+72.7%

iBio, Inc. invested $19K in capex in Q4 2026, funding long-term assets and infrastructure. This represents an increase of 1800.0% from the same quarter a year earlier. Against the prior quarter it is up 72.7%.

R&D Spending

Not reported for Q4 2026.

Share Buybacks

Not reported for Q4 2026.

IBIO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IBIO quarterly income statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$100K-75.0%	$400K+77.8%	$225K	$0-100.0%	$1.9M-20.5%	$2.4M+44.7%	$1.6M-18.8%	$2.0M+354.5%	$444K+12.7%	$394K-58.4%	$948K-48.8%	$1.9M+802.9%	$205K-79.6%	$1.0M-21.1%	$1.3M
Cost of Revenue	N/A	N/A	N/A	N/A	$216K-85.2%	$1.5M+108.0%	$703K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$1.7M+83.5%	$909K-2.8%	$935K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.6M+136.3%	$8.3M+60.3%	$5.2M-49.8%	$10.3M+5.1%	$9.8M-1.6%	$10.0M+179.6%	$3.6M-34.7%	$5.5M+37.3%	$4.0M-3.2%	$4.1M+30.4%	$3.2M-9.7%	$3.5M+84.1%	$1.9M-44.7%	$3.4M-31.1%	$5.0M
SG&A Expenses	$10.6M-0.9%	$10.7M-8.4%	$11.7M-38.6%	$19.0M-12.6%	$21.8M-1.3%	$22.0M+93.8%	$11.4M-7.8%	$12.3M+15.4%	$10.7M+1.3%	$10.6M+37.3%	$7.7M+53.0%	$5.0M+29.2%	$3.9M-8.4%	$4.2M-24.5%	$5.6M
Operating Income	-$35.1M-88.9%	-$18.6M-11.8%	-$16.6M+43.3%	-$29.3M+1.2%	-$29.7M+4.5%	-$31.1M-122.2%	-$14.0M+11.3%	-$15.8M-11.0%	-$14.2M+0.3%	-$14.3M-44.3%	-$9.9M-48.4%	-$6.7M-73.6%	-$3.8M+42.4%	-$6.7M+28.5%	-$9.3M
EBITDA	-$34.5M-93.5%	-$17.8M-13.5%	-$15.7M+44.5%	-$28.3M-7.2%	-$26.4M+7.9%	-$28.7M-144.0%	-$11.8M+24.6%	-$15.6M-24.7%	-$12.5M+0.6%	-$12.6M-40.7%	-$9.0M-42.0%	-$6.3M-81.2%	-$3.5M+45.0%	-$6.3M+29.7%	-$9.0M
Interest Expense	$53K-75.0%	$212K+23.3%	$172K+107.2%	$83K-94.1%	$1.4M-42.5%	$2.5M-0.5%	$2.5M+29.8%	$1.9M-0.8%	$1.9M-0.7%	$1.9M+139.0%	$807K	$0	$0-100.0%	$90K+42.9%	$63K
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	-$32.8M-78.7%	-$18.4M+26.2%	-$24.9M+61.7%	-$65.0M-29.2%	-$50.3M-116.8%	-$23.2M-41.2%	-$16.4M+6.6%	-$17.6M-9.2%	-$16.1M-10.8%	-$14.5M-48.8%	-$9.8M-47.4%	-$6.6M-80.7%	-$3.7M+40.9%	-$6.2M-9.2%	-$5.7M
EPS (Basic)	-$0.32+81.7%	-$1.75+73.1%	-$6.50+93.9%	-$106.19-1737.2%	-$5.78-92.7%	-$3.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.32	-$1.75	-$6.50	-$106.19	-$5.78	-$3.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	104M	10M	4M	612,000	9M	8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q/A	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q/A
Revenue	N/A	N/A	$0-100.0%	$100K	N/A	$0	$200K	$0-100.0%
R&D Expenses	N/A	$3.3M+70.7%	$4.3M+128.0%	$3.5M+172.0%	N/A	$1.9M+110.8%	$1.9M+22.3%	$1.3M-18.7%
SG&A Expenses	N/A	$5.1M+71.9%	$5.2M+88.4%	$2.5M-10.7%	N/A	$3.0M+9.2%	$2.7M-7.4%	$2.8M-21.0%
Operating Income	N/A	-$8.4M-71.4%	-$9.4M-113.7%	-$6.0M-44.9%	N/A	-$4.9M-34.6%	-$4.4M+1.7%	-$4.1M+19.5%
EBITDA	N/A	-$8.2M-75.3%	-$9.3M-120.1%	-$5.8M-47.1%	N/A	-$4.7M-38.2%	-$4.2M+0.8%	-$3.9M+19.6%
Interest Expense	N/A	$22K-59.3%	$41K-28.1%	$36K-36.8%	N/A	$54K+3.8%	$57K+67.6%	$57K+119.2%
Income Tax	N/A	$0	$0	$0	N/A	$0	$0	$0
Net Income	N/A	-$7.7M-59.0%	-$9.0M-106.1%	-$5.7M-43.4%	N/A	-$4.9M-53.2%	-$4.4M+46.9%	-$4.0M+30.6%
EPS (Basic)	-$0.07+77.4%	-$0.06+87.8%	-$0.09+81.3%	-$0.11+76.1%	-$0.31-127.7%	-$0.49+42.4%	-$0.48+89.1%	-$0.46+90.4%
EPS (Diluted)	-$0.07	-$0.06	-$0.09	-$0.11	-$0.31	-$0.49	-$0.48	-$0.46
Diluted Shares (Avg)	N/A	120M	99M	53M	N/A	10M	9M	9M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

IBIO Balance Sheet

IBIO quarterly balance sheet

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$99.1M+327.5%	$23.2M-19.3%	$28.7M-30.3%	$41.2M-58.5%	$99.4M-32.4%	$147.0M+56.0%	$94.2M+207.9%	$30.6M-29.0%	$43.1M+19.6%	$36.0M-30.2%	$51.6M+313.0%	$12.5M+92.4%	$6.5M-30.6%	$9.4M-4.2%	$9.8M
Current Assets	$92.2M+848.7%	$9.7M-38.0%	$15.7M-40.3%	$26.3M-41.7%	$45.1M-56.9%	$104.6M+69.4%	$61.7M+1184.3%	$4.8M-70.5%	$16.3M+90.0%	$8.6M-64.1%	$23.9M+136.2%	$10.1M+158.7%	$3.9M-41.0%	$6.6M-3.8%	$6.9M
Cash & Equivalents	$56.4M+557.1%	$8.6M-39.6%	$14.2M+230.4%	$4.3M-81.0%	$22.7M-70.7%	$77.4M+40.4%	$55.1M+1146.6%	$4.4M0.0%	$4.4M-72.3%	$15.9M0.0%	$15.9M+67.8%	$9.5M+164.5%	$3.6M-18.7%	$4.4M-21.5%	$5.6M
Short-Term Investments	$31.6M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	$0	$0-100.0%	$3.9M+14344.4%	$27K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$0	$0-100.0%	$1.0M+134.7%	$426K+468.0%	$75K-22.7%	$97K+29.3%	$75K-57.1%	$175K-63.8%	$484K+8.8%	$445K+117.1%	$205K-79.6%	$1.0M+186.9%	$351K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.4M+61.3%	$8.3M+12.1%	$7.4M-71.3%	$25.8M-28.1%	$35.9M-6.5%	$38.4M+2.2%	$37.6M+33.6%	$28.1M+4.5%	$26.9M-0.6%	$27.1M-35.0%	$41.7M+3198.7%	$1.3M+219.7%	$395K-90.8%	$4.3M+19.2%	$3.6M
Current Liabilities	$11.7M+92.4%	$6.1M+59.0%	$3.8M-82.6%	$22.1M-27.4%	$30.4M+358.0%	$6.6M+26.9%	$5.2M+51.4%	$3.5M+69.9%	$2.0M+1.1%	$2.0M-12.1%	$2.3M+81.4%	$1.3M+219.7%	$395K-90.8%	$4.3M+19.2%	$3.6M
Non-Current Liabilities	$1.7M-24.9%	$2.2M-38.4%	$3.6M-4.0%	$3.7M-32.2%	$5.5M-82.7%	$31.8M-1.8%	$32.3M+31.1%	$24.7M-0.9%	$24.9M-0.8%	$25.1M-36.3%	$39.4M	$0	$0	$0	$0
Total Equity	$85.7M+476.0%	$14.9M-30.2%	$21.3M+38.6%	$15.4M-75.8%	$63.5M-41.5%	$108.6M+91.8%	$56.6M+2198.7%	$2.5M-84.8%	$16.2M+81.4%	$8.9M-10.3%	$9.9M-11.5%	$11.2M+84.1%	$6.1M+20.3%	$5.1M-17.8%	$6.2M
Retained Earnings	-$365.3M-9.9%	-$332.2M-5.9%	-$313.8M-8.6%	-$288.9M-29.0%	-$223.9M-29.0%	-$173.6M-15.4%	-$150.4M-42.1%	-$105.8M-19.9%	-$88.2M-22.3%	-$72.1M-25.2%	-$57.6M-20.4%	-$47.8M-16.1%	-$41.2M-9.8%	-$37.5M-19.8%	-$31.3M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q/A	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q/A
Total Assets	$99.1M+327.5%	$85.8M+349.3%	$64.4M+196.8%	$64.2M+161.7%	$23.2M-19.3%	$19.1M-61.9%	$21.7M-36.2%	$24.5M-34.9%
Current Assets	$92.2M+848.7%	$77.3M+1174.8%	$53.4M+544.2%	$50.8M+333.8%	$9.7M-38.0%	$6.1M-83.2%	$8.3M-57.9%	$11.7M-49.2%
Cash & Equivalents	$56.4M+557.1%	$47.6M+860.5%	$28.7M+308.7%	$28.1M+154.7%	$8.6M-39.6%	$5.0M-6.5%	$7.0M+151.6%	$11.0M+655.5%
Short-Term Investments	$31.6M	$27.2M	$24.0M	$21.5M	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	$65K	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$13.4M+61.3%	$8.3M+7.4%	$7.8M+0.4%	$8.1M+20.0%	$8.3M+12.1%	$7.7M-69.5%	$7.8M-68.6%	$6.8M-72.4%
Current Liabilities	$11.7M+92.4%	$6.5M+20.5%	$5.9M+25.3%	$6.0M+74.3%	$6.1M+59.0%	$5.4M-74.8%	$4.7M-78.2%	$3.5M-83.2%
Non-Current Liabilities	$1.7M-24.9%	$1.8M-22.9%	$1.9M-37.5%	$2.1M-37.2%	$2.2M-38.4%	$2.3M-39.8%	$3.1M-5.5%	$3.3M-12.4%
Total Equity	$85.7M+476.0%	$77.5M+581.3%	$56.6M+307.1%	$56.0M+215.6%	$14.9M-30.2%	$11.4M-54.2%	$13.9M+51.1%	$17.8M+34.4%
Retained Earnings	-$365.3M-9.9%	-$354.7M-8.4%	-$346.9M-7.7%	-$337.9M-6.3%	-$332.2M-5.9%	-$327.1M-6.9%	-$322.2M-6.4%	-$317.8M-7.9%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

IBIO Cash Flow Statement

IBIO quarterly cash flow statement

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	-$23.2M-51.7%	-$15.3M+17.5%	-$18.6M+39.0%	-$30.4M+18.8%	-$37.5M-24.7%	-$30.1M-125.3%	-$13.3M+4.5%	-$14.0M-3.7%	-$13.5M-2.4%	-$13.2M-63.1%	-$8.1M-70.8%	-$4.7M-14.8%	-$4.1M+15.1%	-$4.8M+19.3%	-$6.0M
Depreciation & Amortization	$646K-16.6%	$775K-16.6%	$929K-9.3%	$1.0M-68.7%	$3.3M+35.7%	$2.4M+7.7%	$2.2M+1152.0%	$179K-89.5%	$1.7M+2.0%	$1.7M+78.3%	$940K+159.0%	$363K+0.6%	$361K+6.8%	$338K+2.5%	$330K
Stock-Based Compensation	$1.4M-10.3%	$1.5M-24.9%	$2.0M-53.6%	$4.4M+0.3%	$4.4M+176.0%	$1.6M+308.8%	$388K+61.0%	$241K-68.7%	$770K-23.8%	$1.0M-18.9%	$1.2M+36.2%	$914K-15.0%	$1.1M-14.9%	$1.3M-52.9%	$2.7M
Capital Expenditures	$578K+3512.5%	$16K-92.4%	$210K-96.3%	$5.7M-21.7%	$7.3M+49.0%	$4.9M+356.4%	$1.1M+17.2%	$920K-1.5%	$934K-29.4%	$1.3M+1845.6%	$68K+423.1%	$13K+225.0%	$4K-42.9%	$7K+600.0%	$1K
Free Cash Flow	-$23.8M-55.3%	-$15.3M+18.4%	-$18.8M+48.1%	-$36.2M+19.3%	-$44.8M-28.1%	-$35.0M-142.6%	-$14.4M+3.2%	-$14.9M-3.3%	-$14.4M+0.5%	-$14.5M-78.0%	-$8.1M-71.8%	-$4.7M-15.0%	-$4.1M+15.2%	-$4.9M+19.2%	-$6.0M
Investing Cash Flow	-$32.0M-4412.5%	$742K-18.1%	$906K-87.1%	$7.0M+236.7%	-$5.1M+80.6%	-$26.5M-2194.5%	-$1.2M-16.6%	-$990K+8.2%	-$1.1M+32.3%	-$1.6M	N/A	N/A	N/A	-$195K+20.4%	-$245K
Financing Cash Flow	$103.0M+1054.1%	$8.9M-63.5%	$24.5M+964.5%	$2.3M+137.6%	-$6.1M-107.8%	$78.8M+20.9%	$65.2M+1788.0%	$3.5M-84.6%	$22.4M+13280.0%	-$170K	N/A	N/A	N/A	$3.8M-57.6%	$9.0M

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q/A	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q/A
Operating Cash Flow	-$6.2M-35.0%	-$6.1M-95.9%	-$5.2M-35.5%	-$5.7M-52.5%	-$4.6M+4.9%	-$3.1M+15.0%	-$3.9M+17.8%	-$3.7M+30.4%
Depreciation & Amortization	$152K-21.6%	$152K-21.2%	$146K-25.1%	$196K+1.6%	$194K-11.4%	$193K-17.9%	$195K-17.7%	$193K-18.9%
Stock-Based Compensation	N/A	$377K+1.9%	$253K-46.7%	$323K-22.2%	N/A	$370K-18.5%	$475K+4.6%	$415K-45.8%
Capital Expenditures	$19K+1800.0%	$11K-21.4%	$516K+51500.0%	$32K	$1K-99.5%	$14K	$1K	$0
Free Cash Flow	-$6.2M-35.3%	-$6.1M-95.4%	-$5.8M-48.8%	-$5.7M-53.4%	-$4.6M+8.8%	-$3.1M+14.6%	-$3.9M	-$3.7M
Investing Cash Flow	-$4.4M-9904.4%	-$3.1M-22121.4%	-$3.0M-149050.0%	-$21.5M-3114.4%	$45K+131.3%	-$14K-101.4%	-$2K	$713K+1326.0%
Financing Cash Flow	$19.4M+137.2%	$28.2M+2548.5%	$8.8M+5879.6%	$46.7M+28930.2%	$8.2M-37.0%	$1.1M-78.8%	-$152K-103.8%	-$162K-106.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IBIO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IBIO quarterly financial ratios

Metric	FY2610-K	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	N/A	N/A	N/A	N/A	88.5%+50.2pp	38.3%-18.7pp	57.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-35141.0%	-4650.5%	-7392.9%	N/A	-1576.3%	-1312.1%	-854.9%	-782.4%	-3204.3%	-3622.8%	-1043.6%	-360.1%	-1873.2%	-662.1%	-730.4%
Net Margin	-33044.0%	-4595.0%	-11071.1%	N/A	-2670.0%	-978.8%	-1003.6%	-871.8%	-3627.3%	-3688.3%	-1030.0%	-357.9%	-1788.3%	-615.5%	-444.5%
Return on Equity	-38.3%+85.2pp	-123.5%-6.7pp	-116.8%+305.8pp	-422.7%-343.4pp	-79.2%-57.9pp	-21.4%+7.7pp	-29.0%+685.3pp	-714.3%-614.7pp	-99.6%+63.4pp	-163.0%-64.8pp	-98.3%-39.3pp	-59.0%+1.1pp	-60.1%+62.2pp	-122.3%-30.3pp	-92.0%
Return on Assets	-33.1%+46.1pp	-79.3%+7.4pp	-86.7%+71.1pp	-157.8%-107.2pp	-50.6%-34.8pp	-15.8%+1.7pp	-17.4%+40.1pp	-57.5%-20.1pp	-37.4%+3.0pp	-40.4%-21.4pp	-18.9%+34.1pp	-53.0%+3.4pp	-56.5%+9.8pp	-66.3%-8.1pp	-58.1%
Current Ratio	7.85+6.3x	1.59-2.5x	4.08+2.9x	1.19-0.3x	1.48-14.3x	15.74+3.9x	11.79+10.4x	1.39-6.6x	8.00+3.7x	4.26-6.2x	10.43+2.4x	8.01-1.9x	9.91+8.4x	1.55-0.4x	1.92
Debt-to-Equity	0.16-0.4x	0.56+0.2x	0.35-1.3x	1.68+1.1x	0.57+0.2x	0.35-0.3x	0.66-10.8x	11.42+9.8x	1.67-1.4x	3.04-1.2x	4.19+4.1x	0.110.0x	0.06-0.8x	0.85+0.3x	0.58
Asset Turnover	0.000.0x	0.020.0x	0.010.0x	0.000.0x	0.020.0x	0.020.0x	0.020.0x	0.07+0.1x	0.010.0x	0.010.0x	0.02-0.1x	0.15+0.1x	0.03-0.1x	0.110.0x	0.13
FCF Margin	-23796.0%	-3830.0%	-8339.6%	N/A	-2378.5%	-1475.5%	-880.5%	-738.1%	-3246.4%	-3676.7%	-858.6%	-256.0%	-2009.8%	-482.2%	-470.7%

Metric	Q4'2610-K	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q/A	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q/A
Operating Margin	N/A	N/A	N/A	-5951.0%	N/A	N/A	-2209.5%	N/A
Net Margin	N/A	N/A	N/A	-5720.0%	N/A	N/A	-2182.0%	N/A
Return on Equity	N/A	-10.0%+32.7pp	-15.9%+15.5pp	-10.2%+12.3pp	N/A	-42.7%-29.9pp	-31.4%+57.9pp	-22.5%+21.0pp
Return on Assets	N/A	-9.0%+16.4pp	-14.0%+6.1pp	-8.9%+7.4pp	N/A	-25.4%-19.1pp	-20.1%+4.0pp	-16.3%-1.0pp
Current Ratio	7.85+6.3x	11.88+10.8x	9.04+7.3x	8.39+5.0x	1.59-2.5x	1.12-0.6x	1.76+0.8x	3.37+2.3x
Debt-to-Equity	0.16-0.4x	0.11-0.6x	0.14-0.4x	0.14-0.2x	0.56+0.2x	0.68-0.3x	0.56-2.1x	0.38-1.5x
Asset Turnover	N/A	N/A	0.000.0x	0.000.0x	N/A	0.00	0.01	0.000.0x
FCF Margin	N/A	N/A	N/A	-5697.0%	N/A	N/A	-1935.0%	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
iBio, Inc. IBIO	FY2026	$100K	-$32.8M	N/A	$54.0M	—
Evaxion A/S EVAX	FY2025	$7.5M	-$7.7M	N/A	$36.5M	30/100
Pulmatrix, Inc. PULM	FY2025	N/A	-$5.2M	N/A	$5.2M	—
GeoVax Labs, Inc. New GOVX	FY2025	$2.5M	-$21.5M	N/A	$2.1M	45/100
Lexaria Bioscience Corp. LEXX	FY2025	$706K	-$11.9M	N/A	$5.6M	—
Lisata Therapeutics, Inc. LSTA	FY2025	$170K	-$17.0M	N/A	$11.2M	—

Where iBio, Inc. Ranks

Frequently Asked Questions

What is iBio, Inc.'s annual revenue?

iBio, Inc. (IBIO) reported $100K in total revenue for fiscal year 2026. This represents a -75.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is iBio, Inc.'s revenue growing?

iBio, Inc. (IBIO) revenue declined by 75.0% year-over-year, from $400K to $100K in fiscal year 2026.

Is iBio, Inc. profitable?

No, iBio, Inc. (IBIO) reported a net income of -$32.8M in fiscal year 2026.

What is iBio, Inc.'s EBITDA?

iBio, Inc. (IBIO) had EBITDA of -$34.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is iBio, Inc.'s return on equity (ROE)?

iBio, Inc. (IBIO) has a return on equity of -38.3% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is iBio, Inc.'s free cash flow?

iBio, Inc. (IBIO) recorded an outflow of $23.8M in free cash flow during fiscal year 2026. This represents a -55.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is iBio, Inc.'s operating cash flow?

iBio, Inc. (IBIO) recorded an outflow of $23.2M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are iBio, Inc.'s total assets?

iBio, Inc. (IBIO) had $99.1M in total assets as of fiscal year 2026, including both current and long-term assets.

What are iBio, Inc.'s capital expenditures?

iBio, Inc. (IBIO) invested $578K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does iBio, Inc. spend on research and development?

iBio, Inc. (IBIO) invested $19.6M in research and development during fiscal year 2026.

How many shares does iBio, Inc. have outstanding?

iBio, Inc. (IBIO) had 64M shares outstanding as of fiscal year 2026.

What is iBio, Inc.'s current ratio?

iBio, Inc. (IBIO) had a current ratio of 7.85 as of fiscal year 2026, which is generally considered healthy.

What is iBio, Inc.'s debt-to-equity ratio?

iBio, Inc. (IBIO) had a debt-to-equity ratio of 0.16 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is iBio, Inc.'s return on assets (ROA)?

iBio, Inc. (IBIO) had a return on assets of -33.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is iBio, Inc.'s P/E ratio?

iBio, Inc. (IBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $54.0M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is iBio, Inc.'s price-to-sales ratio?

iBio, Inc. (IBIO) trades at 540x sales, its market capitalization divided by revenue of $100K revenue, FY2026. The market capitalization is $54.0M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does iBio, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, iBio, Inc. (IBIO) held $88.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.2M over that year. Dividing the one by the other, the reported balance equals about 46 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is iBio, Inc.'s Altman Z-Score?

iBio, Inc. (IBIO) has an Altman Z-Score of -2.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is iBio, Inc.'s Piotroski F-Score?

iBio, Inc. (IBIO) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are iBio, Inc.'s earnings high quality?

iBio, Inc. (IBIO) reported a net loss of $32.8M while operations used $23.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can iBio, Inc. cover its interest payments?

iBio, Inc. (IBIO) reported an operating loss of $35.1M against $53K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.